Skip to main content
. 2023 Jan 23;12(3):e220113. doi: 10.2217/cer-2022-0113

Figure 4. . Two-way sensitivity analysis: relationship between cost–effectiveness and clinical efficacy of IMI/REL relative to CMS+IMI.

Figure 4. 

Green cells indicate that IMI/REL is considered cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained; red cells indicate that IMI/REL is not considered cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained.

IMI/REL: Imipenem/cilastatin/relebactam; PIP/TAZ: Piperacillin/tazobactam.